추천 제품
제품명
Anti-NRAS (C-terminal) antibody produced in rabbit, IgG fraction of antiserum
생물학적 소스
rabbit
Quality Level
항체 형태
IgG fraction of antiserum
항체 생산 유형
primary antibodies
클론
polyclonal
양식
buffered aqueous solution
분자량
predicted mol wt ~21 kDa
종 반응성
human
향상된 검증
recombinant expression
Learn more about Antibody Enhanced Validation
기술
immunoblotting: 1:2,000-1:4,000 using human HEK-293T cells over-expressing NRAS protein
UniProt 수납 번호
배송 상태
dry ice
저장 온도
−20°C
타겟 번역 후 변형
unmodified
유전자 정보
human ... NRAS(4893)
일반 설명
Transforming protein N-Ras (NRAS), also known as GTPase NRas or Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog, is a member of the Ras protein family and are low molecular-weight GTPases. NRAS is mapped to human chromosome location 1p13.2 and shows ubiquitous expression. Ras proteins have highly homologous primary amino acid sequence and differ in their C-terminal region termed as hypervariable region (HVR).
특이성
Anti-NRAS (C-terminal) antibody specifically recognizes human NRAS and does not cross-react with HRAS or KRAS.
면역원
Synthetic peptide from the internal region of human NRAS protein, conjugated to KLH
애플리케이션
Anti-NRAS (C-terminal) antibody produced in rabbit has been used in immunoblotting.
생화학적/생리학적 작용
Neuroblastoma RAS Viral (V-Ras) Oncogene Homolog (NRAS) was the first melanoma oncogene to be identified. Oncogenic NRAS mutations are single base substitutions (most commonly affecting residues G12, G13, or Q61) that lead to the stabilization of GTP binding and constitutive activation of RAS and downstream signaling cascades. Abnormal NRAS activity stimulates several signaling pathways, including mitogen-activated protein kinase (MAPK/ERK), serine/threonine-protein kinase (RAFs) (ARAF, BRAF, and CRAF), phosphatidylinositol 3-kinase (PI3K) and the RAS-like protein (RAL) guanine nucleotide exchange factors (GEFs) signaling pathways. This leads to uncontrolled cell proliferation, resistance to apoptosis and thus cancer therapy potential target. NRAS mutations are present in various cancers, including melanomas, acute myeloid leukemia, colon, thyroid and lung cancers. Mutations are also implicated in hematologic malignancies, including acute lymphocytic leukemia, myelodysplastic syndrome, multiple myeloma and chronic myelomonocytic leukemia.
물리적 형태
Solution in 0.01 M phosphate buffered saline, pH 7.4, containing 15 mM sodium azide.
저장 및 안정성
For continuous use, store at 2–8 °C for up to one month. For extended storage, freeze in working aliquots. Repeated freezing and thawing is not recommended. If slight turbidity occurs upon prolonged storage, clarify the solution by centrifugation before use. Working dilution samples should be discarded if not used within 12 hours.
면책조항
Unless otherwise stated in our catalog, our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
적합한 제품을 찾을 수 없으신가요?
당사의 제품 선택기 도구.을(를) 시도해 보세요.
Storage Class Code
10 - Combustible liquids
WGK
WGK 3
Flash Point (°F)
Not applicable
Flash Point (°C)
Not applicable
가장 최신 버전 중 하나를 선택하세요:
Genetic alterations in RAS-regulated pathway in acral lentiginous melanoma
Puig-Butille JA, et al.
Experimental Dermatology, 22(2), 148-150 (2013)
Esther Castellano et al.
Genes & cancer, 2(3), 216-231 (2011-07-23)
H-ras, N-ras, and K-ras are canonical ras gene family members frequently activated by point mutation in human cancers and coding for 4 different, highly related protein isoforms (H-Ras, N-Ras, K-Ras4A, and K-Ras4B). Their expression is nearly ubiquitous and broadly conserved
Eva Muñoz-Couselo et al.
OncoTargets and therapy, 10, 3941-3947 (2017-09-02)
Melanoma is one of the most common cutaneous cancers worldwide. Activating mutations in RAS oncogenes are found in a third of all human cancers and NRAS mutations are found in 15%-20% of melanomas. The NRAS-mutant subset of melanoma is more
Ha Linh Vu et al.
Pharmacological research, 107, 111-116 (2016-03-19)
Cutaneous melanoma is a devastating form of skin cancer and its incidence is increasing faster than any other preventable cancer in the United States. The mutant NRAS subset of melanoma is more aggressive and associated with poorer outcomes compared to
Douglas B Johnson et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 20(16), 4186-4192 (2014-06-05)
Successful targeting of specific oncogenic "driver" mutations with small-molecule inhibitors has represented a major advance in cancer therapeutics over the past 10 to 15 years. The most common activating oncogene in human malignancy, RAS (rat sarcoma), has proved to be
자사의 과학자팀은 생명 과학, 재료 과학, 화학 합성, 크로마토그래피, 분석 및 기타 많은 영역을 포함한 모든 과학 분야에 경험이 있습니다..
고객지원팀으로 연락바랍니다.